Related Experiment Videos
When is molecular genetic testing for colorectal cancer indicated?
1Clinical Research Centre of the Royal Brisbane Hospital Research Foundation, Bancrift Centre, Herston 4029, Brisbane, Australia. barbara_leggett@health.qld.gov.au
Journal of Gastroenterology and Hepatology
|May 2, 2002
Summary
Genetic testing identifies inherited colorectal cancer risks from mutations in syndromes like FAP and HNPCC. While challenging, detecting these specific mutations aids diagnosis and guides family screening for better management.
Area of Science:
- Genetics
- Oncology
- Gastroenterology
Background:
- Several genetic syndromes significantly increase inherited risk for colorectal cancer.
- Identified syndromes include familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal cancer (HNPCC), Peutz-Jeghers syndrome, Cowden's syndrome, and juvenile polyposis.
Purpose of the Study:
- To review the current status of genetic testing for inherited colorectal cancer syndromes.
- To discuss the clinical utility and limitations of genetic mutation detection in affected families.
Main Methods:
- Review of identified genetic mutations associated with high-risk colorectal cancer syndromes.
- Discussion of the technical challenges and diagnostic implications of mutation detection.
Main Results:
- Specific genetic mutations for major inherited colorectal cancer syndromes are identified.
- Mutation detection is technically demanding due to family-specific mutations.
- Clinical genetic testing confirms diagnoses and predicts risk for family members, guiding endoscopic screening.
Conclusions:
- Genetic testing is diagnostically valuable when a mutation is detected, enabling better management of affected families.
- Current technology limitations mean negative results in affected individuals are unhelpful for predictive testing.